What is Pyxis Oncology's market cap?

Pyxis Oncology (PYXS) has a market capitalization of $184.4M and trades on NASDAQ.

Who are Pyxis Oncology's competitors?

Pyxis Oncology's key competitors include Corbus Pharmaceuticals, Bicara Therapeutics Inc., Johnson & Johnson, and others. These companies compete in similar markets and product categories.

Who does Pyxis Oncology partner with?

Pyxis Oncology's notable partners include Merck & Co., Inc., Pfizer Inc., Biosion USA, Inc., and others.

What subsidiaries does Pyxis Oncology have?

Pyxis Oncology's subsidiaries include Apexigen, Inc..

Where is Pyxis Oncology headquartered?

Pyxis Oncology is headquartered in United States of America and employs approximately 51 people. It has been publicly traded since 2021.

Pyxis Oncology

PYXS

Pyxis Oncology is a clinical-stage biotechnology company focused on developing next-generation therapeutics for difficult-to-treat solid tumors.

Market cap

$184.36M+159%

Table of contents

Earnings

Q1 2026 report

May 14, 2026

EPS-$0.37Miss by $0.02

Read the full report

Next report

Aug 13, 2026 (In 2 weeks)

Revenue estimate$33.3K

EPS estimate-$0.34

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

Gilead Sciences$162.05B+15.3%

IDEAYA Biosciences, Inc.$3.5B+61.5%

Arcus Biosciences$3.5B+236%

Immunome$2.6B+171%

Bicara Therapeutics$1.8B+184%

Pyxis Oncology$184.4M+143%

Corbus Pharmaceuticals$168.2M+43.4%

By revenue growth

IDEAYA Biosciences, Inc.+5,822%

Arcus Biosciences+67.4%

Johnson & Johnson+8.1%

Gilead Sciences+3.5%

Immunome-63.3%

By net margin

Gilead Sciences30.99%+10.2pp

Johnson & Johnson21.48%-3.5pp

Arcus Biosciences-156.36%+121pp

IDEAYA Biosciences, Inc.-3,921.1%+7,769pp

Immunome-5,593.85%-3,719pp

Profile

Pyxis Oncology is a clinical-stage biotechnology company focused on developing next-generation therapeutics for difficult-to-treat solid tumors. The company specializes in antibody-drug conjugates (ADCs) and immuno-oncology agents designed to target the tumor microenvironment and extracellular matrix. Its core value proposition lies in its proprietary technology platforms, FACT and APXiMAB, which enable the creation of stable, site-specific ADCs with multi-pronged mechanisms of action.

Competitive position

Clinical-stage developer with a lead candidate (MICVO) targeting a novel extracellular matrix protein (EDB+FN) in head and neck cancers.

GeographiesUnited States, European Union, China

Customer segmentsPatients with solid tumors, Pharmaceutical companies, Healthcare systems

Business modelR&D focused, IP Licensing, Biotechnology drug development

SuppliersContract Development and Manufacturing Organizations (CDMOs), Academic research institutions, Specialized raw material suppliers

CustomersBiopharmaceutical partners, Specialized oncology clinics, Licensees for antibody platforms

CountryUnited States of America

Listed2021

Employees51.0

CEOThomas Civik

SectorHealthcare

IndustryBiotechnology

Websitepyxisoncology.com

FilingsSEC EDGAR

Questions, answered.

What is Pyxis Oncology's market cap?: Pyxis Oncology (PYXS) has a market capitalization of $184.4M and trades on NASDAQ.
Who are Pyxis Oncology's competitors?: Pyxis Oncology's key competitors include Corbus Pharmaceuticals, Bicara Therapeutics Inc., Johnson & Johnson, and others. These companies compete in similar markets and product categories.
Who does Pyxis Oncology partner with?: Pyxis Oncology's notable partners include Merck & Co., Inc., Pfizer Inc., Biosion USA, Inc., and others.
What subsidiaries does Pyxis Oncology have?: Pyxis Oncology's subsidiaries include Apexigen, Inc..
Where is Pyxis Oncology headquartered?: Pyxis Oncology is headquartered in United States of America and employs approximately 51 people. It has been publicly traded since 2021.